{"id":1030,"date":"2015-09-04T12:00:08","date_gmt":"2015-09-04T10:00:08","guid":{"rendered":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/"},"modified":"2016-03-07T15:12:47","modified_gmt":"2016-03-07T14:12:47","slug":"notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen","status":"publish","type":"project","link":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/","title":{"rendered":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas."},"content":{"rendered":"<p>[et_pb_section admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Projekttitel&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; text_font_size=&#8221;14&#8243; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<h4><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26340530\/\" target=\"_blank\">NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.<\/a><\/h4>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Autoren&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; text_font_size=&#8221;14&#8243; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>Meder L, K\u00f6nig K, Ozreti\u0107 L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, T Buhl, Hartmann W, Wolf J, Merkelbach-Bruse S, M Eilers, Perner S, Heukamp LC, Buettner R. Int J Cancer.<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Journal+Ver\u00f6ffentlichung&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; text_font_size=&#8221;14&#8243; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>Journal: Int J. Cancer<br \/>\nVer\u00f6ffentlichung: 4. September 2015<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Journal: Int J. Cancer<br \/>\nVer\u00f6ffentlichung: 4. September 2015<\/p>\n","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[40],"project_tag":[],"class_list":["post-1030","project","type-project","status-publish","hentry","project_category-2015-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. - Lung Cancer Group Cologne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. - Lung Cancer Group Cologne\" \/>\n<meta property=\"og:description\" content=\"Journal: Int J. Cancer Ver\u00f6ffentlichung: 4. September 2015\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/\" \/>\n<meta property=\"og:site_name\" content=\"Lung Cancer Group Cologne\" \/>\n<meta property=\"article:modified_time\" content=\"2016-03-07T14:12:47+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/\",\"name\":\"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. - Lung Cancer Group Cologne\",\"isPartOf\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\"},\"datePublished\":\"2015-09-04T10:00:08+00:00\",\"dateModified\":\"2016-03-07T14:12:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/project\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/\",\"name\":\"Lung Cancer Group Cologne\",\"description\":\"Lungenkrebs Studiengruppe K\u00f6ln\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. - Lung Cancer Group Cologne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/","og_locale":"en_US","og_type":"article","og_title":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. - Lung Cancer Group Cologne","og_description":"Journal: Int J. Cancer Ver\u00f6ffentlichung: 4. September 2015","og_url":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/","og_site_name":"Lung Cancer Group Cologne","article_modified_time":"2016-03-07T14:12:47+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/","url":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/","name":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. - Lung Cancer Group Cologne","isPartOf":{"@id":"https:\/\/www.lungcancergroup.de\/en\/#website"},"datePublished":"2015-09-04T10:00:08+00:00","dateModified":"2016-03-07T14:12:47+00:00","breadcrumb":{"@id":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lungcancergroup.de\/en\/project\/notch-ascl1-p53-und-rb-aenderungen-definieren-einen-alternativen-weg-fahr-neuroendokrinen-und-kleinzelligen-lungenkarzinomen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.lungcancergroup.de\/en\/"},{"@type":"ListItem","position":2,"name":"Projects","item":"https:\/\/www.lungcancergroup.de\/en\/project\/"},{"@type":"ListItem","position":3,"name":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas."}]},{"@type":"WebSite","@id":"https:\/\/www.lungcancergroup.de\/en\/#website","url":"https:\/\/www.lungcancergroup.de\/en\/","name":"Lung Cancer Group Cologne","description":"Lungenkrebs Studiengruppe K\u00f6ln","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/comments?post=1030"}],"version-history":[{"count":3,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1030\/revisions"}],"predecessor-version":[{"id":1264,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1030\/revisions\/1264"}],"wp:attachment":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/media?parent=1030"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project_category?post=1030"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project_tag?post=1030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}